v3.26.3
Segment Information - Segment details (Details) - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]    
Research and development expenses $ (5,210) $ (10,747)
General and administration expenses (excluding stock-based payment) (17,817) (13,128)
Stock-based payments expense (7,559) (2,609)
Psychedelic Medicine and Drug Therapies Segment    
Segment Reporting [Line Items]    
Research and development expenses (5,210) (10,747)
General and administration expenses (excluding stock-based payment) (10,018) (10,273)
Stock-based payments expense (7,559) (2,609)
Financing expense $ (883) $ (24,563)